Skip to main content
SpringerLink
Log in

Dofetilide promising in supraventricular arrhythmias

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

The class III antiarrhythmic agent dofetilide shows potential in a variety of supraventricular arrhythmias. It appears to have a satisfactory adverse effect profile with low proarrhythmic potential and no negative inotropic effects. The results of a number of studies examining the use of dofetilide in supraventricular arrhythmias were presented at the 47th Annual Scientific Sessions of the American College of Cardiology [ Atlanta, US; March 1998 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Gill Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G. Dofetilide promising in supraventricular arrhythmias. Inpharma Wkly. 1137, 11–12 (1998). https://doi.org/10.2165/00128413-199811370-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811370-00018

Keywords

Search

Navigation